News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Bishal Gyawali addressed G7 cancer drug approval claims about Canada with the Lancet Oncology Study
Bishal Gyawali/scri.queensu.ca
May 21, 2025, 17:41

Bishal Gyawali addressed G7 cancer drug approval claims about Canada with the Lancet Oncology Study

Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X about the article co-authored with Kristina Jenei et al., published in The Lancet Oncology:

“The pervasive narrative in the media/news about Canada being the last country among G7 to approve cancer drugs or to approve fewest cancer drugs is objectively false. I know because my group has studied this. Link in next comment.
Context- this TorontoStar article that cites worry from both Prime Minister of Canada and Doug Ford regarding Canada being the worst among G7 countries regarding access to cancer drugs. But that’s not true.”

Bishal Gyawali

Title: Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study

Journal: The Lancet Oncology

Authors: Kristina Jenei, Adam J. N. Raymakers, Arnaud Bayle, Karin Berger-Thürmel, Avi Cherla, Kazunori Honda, Christopher C. G. A. Jackson, Deme Karikios, Dario Trapani, Scott Berry, Bishal Gyawali

Read the full article.

Bishal Gyawali

Source.

More posts featuring Bishal Gyawali on OncoDaily.

Adam J. N. Raymakers Arnaud Bayle Avi Cherla Bishal Gyawali cancer Christopher C. G. A. Jackson Dario Trapani Deme Karikios Karin Berger-Thürmel Kazunori Honda Kristina Jenei OncoDaily Oncology Queen’s University Scott Berry The Lancet Oncology
Special Coverage
Opinion
May 21, 2025, 17:41
Bishal Gyawali addressed G7 cancer drug approval claims about Canada with the Lancet Oncology Study
Blog
May 21, 2025, 17:33
From Lung Cancer Risk to Response - UICC
Blog
May 21, 2025, 17:25
Rick Buck Presents on AACR Collaboration at Cancer Marketing and Communications Association Meeting
Insight
May 21, 2025, 17:20
Lung Cancer Europe shared study on short-term prehabilitation in resectable NSCLC patients
Insight
May 21, 2025, 17:12
Tanja Obradovic: Issue of Trial Data Applicability to US Patient Population is Resurfacing Again at FDA
Societies
May 21, 2025, 17:07
The American Society of Hematology: Join May 30 webinar on VUS challenges in germline testing
Science
May 21, 2025, 16:57
Guru Sonpavde: CheckMate 901 Trial Data on First-Line Nivolumab in LN-Only Metastatic Urothelial Carcinoma
Blog
May 21, 2025, 16:48
How Can We Build Trust in New Cancer Tools Like Liquid Biopsies? - Lung Cancer Europe
Blog
May 21, 2025, 16:43
The Ohio State’s James Cancer Hospital and Solove Research Institute Represented at the 2025 Race for the Cure
Blog
May 21, 2025, 16:42
Estelamari Rodriguez: Celebrating Clinical Trials Day with the Best Research Staff
Insight
May 21, 2025, 16:38
Catherine Alix-Panabières highlights French-Japanese collaboration on liquid biopsy research in Montpellier
Blog
May 21, 2025, 16:34
Sumanta Pal: The Evolution of Treatments For Prostate Cancer Over The Past 2 Decades